In TKI-naïve patients, afatinib demonstrated activity against major uncommon mutations (median TTF: 12.6 months ORR: 59.0%), ‘other’ mutations (median TTF: 10.7 months ORR: 63.9%) including strong activity against E709X (11.4 months 84.6%) and L747X (14.7 months 80.0%), and compound mutations (11.5 months 63.9%). Overall, median TTF (TKI naïve/pretreated) was 10.7 and 4.5 months. The distribution of mutation categories was: major uncommon (41.4%) exon 20 insertions (22.3%) T790M (20.3%) and ‘others’ (15.9%) 38.6% had compound mutations. Results: Of 1023 patients included, 587 patients were EGFR TKI-naïve and 425 were EGFR TKI-pretreated. Key endpoints were time to treatment failure (TTF) and objective response rate (ORR). Patients with compound mutations (≥2 EGFR mutations) were analyzed separately. Mutations were categorized as T790M-positive, exon 20 insertions, major uncommon (G719X, L861Q, S768I) and ‘others’. Methods: Patients were identified from a prospective database developed by Boehringer Ingelheim and via literature review. Here, we provide an update of >1000 patients, with more data on specific mutations. Introduction: Previously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. 10City of Hope National Medical Center, Los Angeles, CA, United States.9Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.8Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.7Division of Thoracic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.6Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.5Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. ![]()
0 Comments
Leave a Reply. |